ArticleFrontiers in endocrinology2026
The value of machine learning models in predicting lung metastasis in papillary thyroid carcinoma.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To construct a machine learning (ML) model to predict the risk of lung metastasis in papillary thyroid carcinoma (PTC). Methods: This retrospective study included 681 PTC patients who received radioactive iodine (RAI) treatment for the first time. Among them, 71 patients were diagnosed with lung metastasis (10.4%). The patients' age, sex, stimulated thyroglobulin (s-Tg) level ahead of Results: The selected features in the final model included "maximum tumor diameter", "number of invading tumors", and "s-Tg". The RF model had the highest area under the curve (AUC) of 0.935, whereas the SVM had the lowest generalization ability (AUC = 0.863). In the testing of all models, LR achieved an AUC of 0.928. Although the RF model had a slightly higher AUC of 0.935, the LR model was ultimately chosen due to its superior generalization ability as indicated by its highest performance in AUPRC of 0.74 in cross-validation. DCA showed that under most threshold probabilities, the net benefit of the LR model exceeded other models. A nomogram was used to display the LR results. Conclusion: LASSO regression analysis identified that large primary tumor, high number of invading tumors, high s-Tg level ahead of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.